Prognostic Value of PET-Based Metabolic Markers in Nivolumab-Treated NSCLC
Molecular Oncologic Imaging · 2025
DOI: 10.71286/moi.1727407 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncologic Imaging, 2025. Verfasst von Gozde Mutevelizade und 5 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Objective
This study aimed to assess the prognostic significance of 18F-FDG PET/CT metabolic parameters in patients with non-small cell lung cancer (NSCLC) receiving nivolumab as second-line therapy. The study also explored associations between these parameters, treatment response, and survival outcomes.
Methods
A retrospective analysis was performed on 32 stage IV NSCLC patients who received at least four doses of nivolumab and underwent both baseline and follow-up PET/CT scans. Metabolic parameters, including SUVmax, SUVmean, total metabolic tumor volume (tMTV), and total lesion glycolysis (tTLG), were measured. Treatment response was classified according to EORTC criteria. Kaplan–Meier analysis and log-rank tests were applied for survival comparisons, and non-parametric methods evaluate associations.
Results
Patients with partial metabolic response demonstrated significantly longer post-nivolumab survival. Post-treatment SUVmax, SUVmean, and tTLG differed significantly among response categories. Pretreatment tMTV and tTLG, and post-treatment SUVmax, SUVmean, and tTLG, were significantly associated with mortality (p
Zitieren
APA
Mutevelizade, G., Aydin, N., Erdoğan, A. P., Bozdemir, B. C., Kolkıran, N., & S.bilgin, E. (2025). Prognostic Value of PET-Based Metabolic Markers in Nivolumab-Treated NSCLC. Molecular Oncologic Imaging. https://doi.org/10.71286/moi.1727407
Vancouver
Mutevelizade G, Aydin N, Erdoğan AP, Bozdemir BC, Kolkıran N, S.bilgin E. Prognostic Value of PET-Based Metabolic Markers in Nivolumab-Treated NSCLC. Molecular Oncologic Imaging. 2025. doi:10.71286/moi.1727407
BibTeX
@article{Mutevelizade2025,
author = {Mutevelizade, Gozde and Aydin, Nazim and Erdoğan, Atike Pinar and Bozdemir, Bilal Cagri and Kolkıran, Nagihan and S.bilgin, Elvan},
title = {Prognostic Value of PET-Based Metabolic Markers in Nivolumab-Treated NSCLC},
journal = {Molecular Oncologic Imaging},
year = {2025},
doi = {10.71286/moi.1727407}
}
EUVIMED